首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B.
【24h】

Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B.

机译:威尔逊病基因ATP7B的其他剪接变体的突变分析和表征。

获取原文
获取原文并翻译 | 示例
       

摘要

Wilson disease is a copper metabolism disorder caused by mutations in ATP7B, a copper-transporting adenosine triphosphatase. A molecular diagnosis was performed on 135 patients with Wilson disease in Taiwan. We identified 36 different mutations, eight of which were novel: five missense mutations (Ser986Phe, Ile1348Asn, Gly1355Asp, Met1392Lys, and Ala1445Pro), one deletion (2810delT) in the coding region, and two nucleotide substitutions (-133A-->C and -215A-->T) in the promoter region. These mutations were not observed in 100 control subjects and reduced the activity of the mutated protein by at least 50% when compared with wild-type ATP7B. In addition to exon 8, our data indicate another mutation hotspot in exon 12 where 9.62% of all mutations occurred. An alternative splice variant of ATP7B lacking exon 12 was observed in one patient who had a homozygous 2810delT mutation and very mild clinical symptoms. Clinical examination and functional characterization of alternative splice variants of ATP7B lacking exon 12 showed that they retained 80% of their biological activity. The 2810delT mutation increased the expression of these variants, which may have explained the mild symptoms in the patient with the 2810delT mutation. We also discovered that treating liver cancer cells with a Na(+)/H(+) exchanger inhibitor, 5-(N-ethyl-N-isopropyl)-amiloride, significantly enhanced the expression of the alternative splice variant of ATP7B lacking exon 12. CONCLUSION: This study suggests a novel therapeutic strategy for patients with mutations in exon 12.
机译:威尔逊病是由铜转运腺苷三磷酸酶ATP7B突变引起的铜代谢异常。对台湾的135例威尔逊病患者进行了分子诊断。我们鉴定出36个不同的突变,其中8个是新颖的:5个错义突变(Ser986Phe,Ile1348Asn,Gly1355Asp,Met1392Lys和Ala1445Pro),编码区的一个缺失(2810delT)和两个核苷酸取代(-133A-> C -215A-> T)。在100名对照受试者中未观察到这些突变,与野生型ATP7B相比,突变蛋白的活性降低了至少50%。除第8外显子外,我们的数据还显示第12外显子的另一个突变热点,其中发生了9.62%的所有突变。在一名患有纯合2810delT突变且临床症状非常轻微的患者中,观察到另一种缺少外显子12的ATP7B剪接变体。缺少外显子12的ATP7B可变剪接变体的临床检查和功能表征表明,它们保留了80%的生物活性。 2810delT突变增加了这些变异的表达,这可能解释了2810delT突变患者的轻度症状。我们还发现,使用Na(+)/ H(+)交换抑制剂5-(N-乙基-N-异丙基)-阿米洛利治疗肝癌细胞,可显着增强缺少外显子12的ATP7B替代剪接变体的表达。结论:这项研究为外显子12突变的患者提出了一种新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号